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We determined the extent of disease impact in 28 patients with genetically conﬁrmed chronic progressive external ophthalmoplegia
(CPEO) and compared the outcomes to those of matched myotonic dystrophy type I patients.
CPEO patients reported a high frequency of severe fatigue (67.9%), pain (96.2%), depression (32.1%) and dependency in daily life
(46.4%). The frequency and extent of depression were signiﬁcantly higher than in DM1 patients (32.1% vs. 7.1%, p = 0.040; mean Beck’s
depression inventory for primary care score 3.8 ± 3.5 vs. 1.3 ± 1.4, p = 0.001), as were fatigue severity, pain intensity and extent of func-
tional impairments.
CPEO patients with polymerase gamma-1 mutations reported more functional impairments than those with mitochondrial DNA
mutations. Disease impact was however not inﬂuenced by most clinical features. The present results help physicians to identify and
to treat the factors that inﬂuence quality of life in CPEO patients and to provide symptomatic treatment where needed.
 2010 Elsevier B.V.
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Chronic progressive external ophthalmoplegia (CPEO)
is one of the most common mitochondrial disorders in
adults [1]. The deﬁning symptom is a slowly progressive
extraocular muscle weakness. Multi-system involvement
is however common, causing functional impairments sec-
ondary to dysfunction of (proximal) skeletal muscles, ret-
ina, cochlea, cerebrum, cerebellum and heart [2].
The frequency and nature of these impairments (body
level) are well documented in previous studies, but their
impact on daily life activities (individual level) or participa-
tion (society level) are unknown [3–6]. In our experience,
there is often a discrepancy between the generally mild0960-8966  2010 Elsevier B.V.
doi:10.1016/j.nmd.2010.12.008
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Open access under the Elsevier OA license.impairments and the severe limitations in activities and
participation in CPEO patients. This discrepancy may lead
to underestimation of disease impact by the treating physi-
cian, which in turn could result in inadequate symptomatic
treatment at the level of activities and participation.
Here, we used a set of validated questionnaires to sys-
tematically determine disease impact on daily life activities
and participation in a large cohort of CPEO patients from
a single tertiary referral centre. In order to identify possible
associations between disease impact and mutation type or
clinical features we only included patients with a known
causative mutation, and all participants underwent stan-
dardized neurological examinations. To estimate the clini-
cal relevance of our results, we compared questionnaires
outcomes of CPEO patients to those of matched myotonic
dystrophy type I (DM1) patients. DM1 is suitable for
comparison with CPEO since it is a relatively common
B.W. Smits et al. / Neuromuscular Disorders 21 (2011) 272–278 273neuromuscular disorder and therefore well known to many
neurologists. Moreover, like CPEO, DM1 also aﬀects mus-
cle, eye, brain, and heart.
2. Methods
2.1. Patients
All CPEO patients known in Department of Neurology
of the Radboud University Nijmegen Medical Centre were
invited to participate. As there are no commonly accepted
criteria for CPEO, we only included patients with both
characteristic clinical features and a known causative
mutation [2]. Consequently, all participants met the follow-
ing three criteria:
(1) a phenotype including a slowly progressive bilateral
external ophthalmoplegia,
(2) a proven pathogenic mutation or deletion in the
mitochondrial DNA (mtDNA) or in the nuclear
polymerase gamma 1 (POLG1), Twinkle or adenine
nucleotide translocator 1 (ANT1) genes,
(3) exclusion of an alternative diagnosis.
These inclusion criteria also cover two more or less spe-
ciﬁc mitochondrial phenotypes with external ophthalmople-
gia as a key symptom: the Kearns–Sayre syndrome (KSS:
ophthalmoplegia, pigmented retinopathy, age of onset
below 20 years, and at least one of the following symptoms:
cardiac conduction block, cerebellar ataxia, elevated CSF
protein content) and SANDO (Sensoric Atactic Neuropa-
thy, Dysarthria and Ophthalmoplegia) [7–9]. In the present
study, we used the term CPEO to describe all patients meet-
ing the inclusion criteria and the terms KSS and SANDO to
describe the speciﬁc subtypes only.
Age and sex matched controls were selected from a pre-
viously published cohort of genetically conﬁrmed, adult
onset DM1 patients, all of whom attended normal educa-
tion [10]. All participants gave informed consent. Local
ethical committee approved this study and the patients’
consent was obtained according to the Declaration of
Helsinki.
2.2. Questionnaires
We used a set of validated questionnaires to evaluate
several important determinants of disease impact:
2.2.1. Fatigue severity
Experienced fatigue is deﬁned as an overwhelming sense
of tiredness, lack of energy and feeling of exhaustion. We
used the Checklist Individual Strength (CIS) to determine
the severity of experienced fatigue [11]. CIS is a 20-item
questionnaire, which measures the severity of fatigue in
four diﬀerent sub items: fatigue severity (8 items, range
8–56), reduced concentration (5 items, 5–35), reduced
activity (3 items, range 3–21), and reduced motivation (4items, range 4–28). Each item was scored on a seven-point
scale. A CIS fatigue score equal to or higher than 35 indi-
cates severe fatigue [11,12].
2.2.2. Pain
Analgesic use and intensity and location of pain were
assessed with the McGill’s Pain Questionnaire (MPQ)
[13]. Pain intensity was scored on a 100 mm horizontal
visual analogue scale (VAS) and was divided in minimal,
actual and maximal VAS scores. Patients could allocate
pain to one or more of 32 predeﬁned body areas.
2.2.3. Depression
Depression was rated according to the Beck’s Depres-
sion Inventory for Primary Care (BDI-PC) [14]. This is a
7 item self-report instrument composed of cognitive and
aﬀective symptoms. Each item is scored on a 4-point scale.
Scores equal to or higher than 5 indicate depression [14].
BDI-PC was preferred over the complete BDI to avoid
an overlap between physical aspects of fatigue and the
somatic symptoms of depression.
2.2.4. Functional impairments and independency
Functional impairments were assessed with the Dutch
version of the Sickness Impact Proﬁle (SIP-136) [15]. The
136 items are divided into 12 categories: sleep and rest,
emotional behavior, body care and movement, household
management, mobility, social interaction, ambulation,
alertness and intellectual functioning, communication,
work, recreation and pastimes, and eating. The SIP-136
has no validated cut oﬀ value, as healthy controls are by def-
inition free of disease related functional impairments.
The level of independency was assessed with the modi-
ﬁed Rankin scale (mRS), a 7-point observer rated scale.
The mRS scores 0–2 indicate independency in daily life
activities [16]. In all questionnaires, higher scores indicate
more disability.
2.3. Statistical analysis
Data analysis was performed using SPSS (version 17.0)
for Windows. An independent Mann–Whitney U-test was
use to compare means and a Fisher’s exact test to compare
frequencies. Correlations were calculated using a Spearman
coeﬃcient and odds ratios using a binary logistic regres-
sion. Signiﬁcance level was set at p < 0.05 (two-tailed) in
all cases.
3. Results
3.1. Patients
We identiﬁed 30 patients meeting the inclusion criteria.
All were invited to participate, two male patients (one with
an m.12315G>A mutation and one with a mtDNA dele-
tion) refused because of a lack of motivation. In general,
their clinical features and disease severity were in the same
Table 1
Demographic, genetic and clinical data of 28 CPEO patients.
No. Sex/age/age at
onset
Mutation Cerebellar
ataxia
Periph.
neurop.
Dysarthria Cognitive
impairm.
Proximal
myopathy
Retinal/cochlear
involv.
Other
1 F/41/32 Deletion      /+ HT
2 F/28/17 Deletion     + /
3 F/33/14 Deletion      / M
4 M/30/8 Deletion +   + + +/+
5 F/49/25 Deletion     + /
6 F/57/34 Deletion     + / CM,
E
7 M/51/25 Deletion   +  + /
8 M/43/14 Deletion +  + + + +/+ CB
9 F/50/13 Deletion     + /
10 F/56/17 Deletion      /
11 M/57/12 Deletion   +  + /
12 F/45/5 Deletion      /
13 F/35/25 Deletion      /
14 F/42/26 Deletion     + /
15 F/37/12 Deletion +  +  + +/+
16 F/54/29 Deletion +  + + + +/+ AF
17 M/55/30 m.5709T>C      / O, E,
C
18 M/54/48 m.4267A>G     + /
19 F/50/12 m.3243A>G +  +  + /+ DM,
M
20 M/49/12 m.3243A>G  +  +  /+ DM
21 M/75/54 POLG1  + +  + /
22 F/42/30 POLG1 + SAN +  + /
23 M/54/35 POLG1 + SAN + + + /
24 F/48/25 POLG1 + SAN + + + /
25 M/46/39 POLG1 + SAN + + + /
26 M/39/23 POLG1 + SAN +  + /
27 F/48/24 POLG1 + SAN +  + /+
28 M/46/21 POLG1 + SAN + +  /
Abbreviations: age and age at onset in years; C, cataract; CB, cardiac conduction block; CM, cardiomyopathy; DM, diabetes mellitus; E, epilepsy; HT,
hypothyroidism; M, migraine; O, otosclerosis; POLG1, polymerase gamma 1; SAN, sensoric atactic neuropathy.
+ presence of symptom;  absence of symptom.
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women), 16 patients had a single mtDNA deletion, 4 a
pathogenic mtDNA point mutation and 8 a POLG1 muta-
tion (Table 1). POLG1 mutations included a homozygous
A467T in six patients and compound heterozygous
A467T and W748S mutations in two (patients 27 and
28). None of the patients had Twinkle or ANT1 mutations.
Mean disease duration was 23.3 ± 10.6 years and mean age
of onset was 23.6 ± 11.7 years. Three patients met the cri-
teria for KSS and 7 for SANDO.3.2. Questionnaires
3.2.1. Fatigue severity
Severe fatigue (CIS fatigue scoreP35) was the most fre-
quent complaint, being reported by 19 patients (67.9%)
with a mean CIS fatigue score for the whole group of
40.0 ± 12.6. Demographic characteristics, clinical features,
mutation type, and outcomes on all other questionnaires
did not diﬀer between patients with or without severe
fatigue.3.2.2. Pain
CPEO patients mainly reported pain in the upper legs
and head (Fig. 1). Only one patient (3.6%) reported no pain
(actual, minimal and maximal VAS scores = 0 mm).
Twelve patients (42.9%) reported pain on waking up, of
whom 5 had moderate to severe pain. Ten patients
(28.6%) reported limitations in daily activities due to pain.
Among the 27 patients with pain, sixteen (59.3%) used
analgesics, mostly acetaminophen (13 patients, 48.1%),
NSAIDs (7 patients, 25.9%) and opioids (2 patients,
7.4%). Patients using analgesics had higher CIS reduced
concentration (21.1 ± 10.0 vs. 13.5 ± 8.3, p = 0.036) and
SIP sleep and rest scores (104.8 ± 64.1 vs. 47.6 ± 33.2,
p = 0.033) than patients without analgesic use, while there
were no diﬀerences in pain severity.3.2.3. Depression
Depression (BDI-PC score P5) was found in 9 patients
(32.1%) and mean BDI-PC score was 3.8 ± 3.5. Only 2 of
the nine patients with a depression used antidepressants,
together with 2 non-depressed patients. Depression was
Fig. 1. Distribution of pain in CPEO patients showing the percentage of
patients with pain in 32 predeﬁned body areas.
Table 2
Aspects of disease impact in patients with CPEO and DM1.
CPEO (n = 28) DM1 (n = 28)
CIS
Fatigue 40.0 ± 12.6 34.0 ± 10.5 p = 0.035
Concentration 17.9 ± 10.0 18.1 ± 6.2
Motivation 16.4 ± 6.4 14.1 ± 6.2
Activity 13.1 ± 5.9 9.8 ± 5.4 p = 0.044
BDI-PC 3.8 ± 3.5 1.3 ± 1.4 p = 0.001
MPQ
Actual VAS pain 22.5 ± 24.6 9.1 ± 12.1 p = 0.028
Minimal VAS pain 12.0 ± 14.9 7.7 ± 15.4 p = 0.045
Maximal VAS pain 63.3 ± 27.2 30.6 ± 33.8 p = 0.001
SIP
Sleep and rest 93.9 ± 78.6 68.2 ± 61.0
Emotional behavior 116.1 ± 142.3 15.3 ± 29.9 p = 0.001
Body care and movement 367.8 ± 397.0 201.0 ± 184.4
Household management 228.2 ± 180.4 124.0 ± 86.6 p = 0.026
Mobility 135.3 ± 194.2 48.8 ± 91.9
Social interaction 291.3 ± 276.2 109.7 ± 155.4 p = 0.002
Ambulation 167.5 ± 129.3 146.8 ± 125.5
Alertness 224.4 ± 216.9 137.5 ± 132.0
Communication 161.8 ± 168.3 103.9 ± 121.7
Work 160.0 ± 159.4 130.3 ± 144.9
Recreation and pastimes 114.7 ± 95.7 85.9 ± 76.3
Eating 22.8 ± 45.1 4.8 ± 19.2 p = 0.022
Total 2083 ± 1505 1176 ± 821 p = 0.031
Abbreviations: DM1, myotonic dystrophy type 1; CIS, Checklist Individ-
ual Strength; BDI-PC, Beck’s Depression Inventory for Primary Care;
MPQ, McGill’s Pain Questionnaire; VAS, Visual Analogue Scale; SIP,
Sickness Impact Proﬁle.
Scores are expressed as mean ± SD.
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depressed patients had higher CIS reduced motivation
(20.3 ± 4.6 vs. 14.5 ± 6.4, p = 0.012), CIS reduced activity
(16.7 ± 3.6 vs. 11.4 ± 6.1, p = 0.030) and total CIS scores
(101.2 ± 16.9 vs. 80.7 ± 26.1, p = 0.049) compared to non-
depressed patients. Moreover, depressed patients were less
likely to be independent (mRS 62) in daily life activities
(11% vs. 74%, p = 0.004) and had more severe functional
impairments (total SIP score 2993 ± 1380 vs. 1621 ± 1320,
p = 0.017). This diﬀerence in total SIP scoremainly consisted
of signiﬁcantly higher subscores on emotional behavior
(204.9 ± 149.8 vs. 74.0 ± 120.7, p = 0.010), body care and
movement (580.1 ± 428.7 vs. 267.2 ± 348.6, p = 0.025),
mobility (248.7 ± 158.4 vs. 81.6 ± 189.6, p = 0.005), social
interaction (463.6 ± 274.4 vs. 209.7 ± 243.1, p = 0.018),
and ambulation (257.6 ± 110.9 vs. 124.9 ± 116.8, p = 0.005).
3.2.4. Functional impairments and independence
Fifteen patients (53.6%) were independent in daily life
activities (mRS 62), whereas 13 (46.4%) were not (mRS
>2). Patients who were independent in daily life activities
had lower CIS reduced motivation (13.8 ± 5.3 vs. 19.2 ±
6.6, p = 0.015), CIS reduced activity (10.5 ± 5.5 vs.
16.4 ± 5.1, p = 0.011), and total CIS scores (75.4 ± 25.6
vs. 101.1 ± 16.8, p = 0.009) compared to patients who were
not independent. As expected, non-independent patients
reported more severe functional impairments (total SIP
score 2659 ± 1175 vs. 1584 ± 1616, p = 0.018), with signiﬁ-
cantly higher SIP subscores on body care and movement
(497.8 ± 392.9 vs. 255.1 ± 377.3, p = 0.017), mobility(191.0 ± 164.2 vs. 87.1 ± 210.3, p = 0.043), social interac-
tion (377.7 ± 235.9 vs. 216.5 ± 294, p = 0.021), and ambula-
tion (237.6 ± 119.4 vs. 106.8 ± 107.3, p = 0.004), and
communication (239.2 ± 191.2 vs. 94.7 ± 113.5, p = 0.032).
3.3. CPEO vs. DM1 patients
To estimate the clinical relevance of our ﬁndings, we
compared questionnaire results of CPEO patients to those
of age and sex matched DM1 patients. CPEO patients were
more often depressed than DM1 patients (32.1% vs. 7.1%,
p = 0.040). In addition, CPEO patients had higher CIS
fatigue, CIS reduced activity and VAS scores and more
severe functional impairments, indicated by a higher total
SIP score (Table 2). The higher total SIP score mainly con-
sisted of signiﬁcantly higher subscores on emotional behav-
ior, household management, social interaction and eating.
Except for CIS reduced concentration, scores on all other
questionnaires were non-signiﬁcantly higher in CPEO than
in DM1 patients.
3.4. Inﬂuence of clinical features or mutation type on disease
impact
Several clinical features were associated with an
increased risk of depression (Table 3). In contrast, none
of the clinical features was associated with severe fatigue
Table 3
Odds ratios indicating the relation between clinical features and three
aspects of quality of life: fatigue, depression and functional impairments.
Severe fatigue
(CIS fatigue
P35)
Depression
(BDI-PC P5)
Non-independent
(mRS >2)
Cerebellar ataxia 0.5 (0.1–2.3) 9.8 (1.5–63.8)* 4.4 (0.9–21.8)
Peripheral
neuropathy
1.2 (0.2–6.2) 7.5 (1.3–44.1) * 4.7 (0.9–24.8)
Dysarthria 0.7 (0.1–3.5) 2.8 (0.5–14.4) 4.5 (0.9–22.1)
SANDO
phenotype
0.5 (0.1–3.1) 10.6 (1.5–76.1) * 4.1 (0.6–26.1)
Cognitive
impairment
0.7 (0.1–4.0) 6.7 (1.1–40.4) * 2.5 (0.5–13.5)
Proximal myopathy 1.4 (0.3–7.8) 4.7 (0.5–45.5) 3.7 (0.6–22.8)
Retinal involvement 1.5 (0.1–16.8) 2.4 (0.3–20.8) 4.2 (0.4–46.5)
Cochlear
involvement
1.6 (0.3–10.2) 3.0 (0.5–16.7) 2.5 (0.5–13.5)
Abbreviations: CIS, Checklist Individual Strength; BDI-PC, Beck’s
Depression Inventory for Primary Care (BDI-PC); mRS, modiﬁed Rankin
scale; SANDO, sensoric atactic neuropathy, dysarthria, ophthalmoplegia.
Expressed as odds ratio (95% conﬁdence interval).
* p < 0.05.
Table 4
Aspects of disease impact in CPEO patients with mtDNA mutations or
deletions (non-POLG1) versus patients with POLG mutation (POLG1).
CPEO
Non-POLG1
(n = 20)
CPEO
POLG1
(n = 8)
Demographics
Sex (M:F) 7:13 5:3
Age 45.8 ± 9.3 49.8 ± 11.1
Age at onset 20.5 ± 10.7 31.4 ± 11.1 p = 0.041
Disease duration 25.3 ± 11.4 18.4 ± 6.3
CIS
Fatigue 40.7 ± 12.9 38.5 ± 12.4
Concentration 18.1 ± 10.7 17.3 ± 8.3
Motivation 15.1 ± 5.4 19.5 ± 7.9
Activity 12.6 ± 6.0 14.4 ± 5.9
BDI-PC 3.6 ± 3.7 4.5 ± 2.9
MPQ
Actual VAS pain 25.3 ± 23.5 15.0 ± 27.5
Minimal VAS pain 12.8 ± 13.9 9.7 ± 18.6
Maximal VAS pain 65.6 ± 23.8 57.1 ± 36.3
SIP
Sleep and rest 100.1 ± 82.1 78.6 ± 71.9
Emotional behavior 120.1 ± 150.2 106.1 ± 129.1
Body care and movement 204.3 ± 208.8 776.4 ± 471.7 p = 0.001
Household management 172.6 ± 138.6 367.1 ± 206.1 p = 0.019
Mobility 103.7 ± 195.4 214.4 ± 178.4
Social interaction 206.6 ± 248.1 503.3 ± 235.0 p = 0.003
Ambulation 122.4 ± 98.9 280.5 ± 132.4 p = 0.007
Alertness 213.4 ± 229.1 251.9 ± 194.6
Communication 113.0 ± 127.1 283.8 ± 203.8 p = 0.032
Work 158.9 ± 158.3 162.8 ± 173.3
Recreation and pastimes 103.8 ± 100.2 142.0 ± 82.8
Eating 16.6 ± 40.2 38.5 ± 55.4
Total 1635 ± 1317 3205 ± 1421 p = 0.011
Modiﬁed Rankin scale 2.2 ± 1.0 3.3 ± 0.9 p = 0.017
Abbreviations: CIS, Checklist Individual Strength; BDI-PC, Beck’s
Depression Inventory for Primary Care; MPQ, McGill’s Pain Question-
naire; mtDNA, mitochondrial DNA; POLG1, polymerase gamma 1; VAS,
Visual Analogue Scale; SIP, Sickness Impact Proﬁle.
Scores are expressed as mean ± SD.
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strong tendency towards an association between non-inde-
pendency and cerebellar ataxia, peripheral neuropathy and
dysarthria. Also, fatigue severity, depression, pain and level
of independency were not inﬂuenced by sex, age or disease
duration.
The SANDO phenotype was only present in patients
with POLG1 mutations, while only one of the patients with
POLG1 mutations had a clinical phenotype diﬀerent from
SANDO.
Patients with POLG1 mutations had more functional
impairments (i.e. a higher total SIP score), with higher
SIP subscores on body care and movement, household
management, social interaction, ambulation, and commu-
nication (Table 4). The percentage of patients being inde-
pendent in daily activities did not diﬀer between patients
with POLG1 mutations and patients with mitochondrial
DNA mutations or deletions (mRS 0–2: 75% vs. 35%,
p = 0.096). However, moderately severe disability
(mRS = 4: unable to walk without assistance and unable
to attend to own bodily needs without assistance) was more
common in patients with POLG1 mutations (50.0% vs.
11.1%, p = 0.032). Fatigue severity, depression and pain
did not diﬀer between patients with or without POLG1
mutations. However, depression was more common in
patients with SANDO phenotype than in patients with
non-SANDO phenotypes (71% vs. 19%, p = 0.020).
4. Discussion
We showed that severe fatigue, depression, pain and
functional impairments contribute to disease impact in
CPEO patients. We also found that disease impact was
related to the mutation type, as patients with POLG1
mutations had more severe functional impairments than
patients with mtDNA mutations or deletions.We demonstrated that severe fatigue, deﬁned as an over-
whelming sense of tiredness, lack of energy and feeling of
exhaustion was present in the majority of CPEO patients.
Moreover, we found that severe fatigue was more common
in CPEO than in DM1 or in several other neuromuscular
disorders [17]. The excessive fatigue reported by CPEO
patients could in part be attributed to exercise intolerance,
a key symptom in mitochondrial myopathies [18]. How-
ever, the CIS fatigue questionnaire which we used to rate
fatigue severity covers multiple aspects of fatigue. CIS fati-
gue questionnaire scores were uniformly high on all aspects
and we therefore think that fatigue in CPEO is more than
exercise intolerance alone.
The high frequency of depression in this study is consis-
tent with previous reports on CPEO as well as reports on
other mitochondrial disorders [19–25]. It is however, in
contrast to other chronic neuromuscular disorders such
as DM1, hereditary motor and sensor neuropathy type I
and facioscapulohumoral dystrophy, which are not
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discrepancy between mitochondrial disorders and other
neuromuscular disorders suggests a causative relation
between mitochondrial dysfunction and an increased risk
of depression. This concept is supported by the previously
reported association between mood disorders and
decreased cerebral metabolic activity [26–28]. The frontal
lobes may play a particularly important role in the develop-
ment of depression in mitochondrial disorders since they
have an important function in mood regulation, carry a rel-
atively high percentage of mutant mitochondrial DNA and
have a relatively high metabolic demand [29–31].
Patients with POLG1 mutations had more functional
impairments than patients with mtDNA point mutations
or deletions, despite a (non-signiﬁcantly) shorter disease
duration. Since there were no diﬀerences in concentration,
motivation, activity and depression, these aspects of disease
impact cannot explain the increased functional impair-
ments in patients with POLG1 mutations. POLG1 muta-
tions were however strongly associated with a sensoric
atactic neuropathy, which is a debilitating syndrome and
may therefore account for the increased functional impair-
ments in patients with POLG1 mutations [32].
To estimate the clinical relevance of our results, we com-
pared questionnaires outcomes of CPEO patients to those of
matched DM1 patients. Although disease impact in DM1 is
commonly considered to be profound, CPEO patients more
frequently andmore seriously suﬀered fromdepression, pain
and functional impairments in several domains (emotional
behavior, household management, social interaction, and
eating), while fatigue severity and limitations in almost all
other domains were at least equal to DM1 [33,34].
Literature on disease impact in CPEO is limited. The
present results conﬁrm and extend previous ﬁndings of lim-
itations in health related physical and common role activi-
ties, and perception of impaired general health and vitality
in CPEO patients [35]. However, in contrast to our results,
this previous study found normal subjective perception of
mental health and normal social activities, and a low fre-
quency of depression. The discrepancy between the former
and the present study might be explained by the fact that
we used a more extensive set of validated questionnaires
to evaluate a wider range of quality of life aspects.
This study has several methodological limitations. First,
the cross sectional design makes it impossible to determine
the direction of associations. A longitudinal study design
should be performed to diﬀerentiate between causes and
consequences. Second, although our study population is
one of the largest ever published in a prospective clinical
study on genetically conﬁrmed CPEO patients, sample size
is still small for extensive statistical analysis. As a conse-
quence, possible relations and correlations might not be
detected. Since CPEO is a rare disorder, inclusion of more
genetically conﬁrmed patients is very diﬃcult. Last, this is a
single centre study from a tertiary referral clinic. Our study
population might therefore not be representative for the
total population of CPEO patients. However, since theprevalence of CPEO is low and the diagnosis of CPEO
requires specialized techniques, nearly all CPEO patients
in the Netherlands are referred to a tertiary referral clinic.
Moreover, since this study has a high participation rate, we
think that the study population is indeed representative.
In conclusion, CPEO causes a profound impact on
social and daily life activities, which is indeed more than
meets the eye. From our data we conclude that manage-
ment of CPEO patients should include screening for the
main aspects of disease impact: fatigue, depression, pain,
and functional impairments. As there is no cure for CPEO,
symptomatic treatment of these aspects may improve qual-
ity of life. For this purpose we suggest a multidimensional
approach aimed at the speciﬁc needs of the individual
patient. This approach may include rehabilitation and
medication for the treatment of depression or pain.Author contributions and disclosures
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